Purple Biotech (PPBT) Share-based Compensation (IS) (2017 - 2026)
Purple Biotech (PPBT) reported Share-based Compensation (IS) of $93000.0 for Q1 2026, little changed year-over-year from $93000.0 in Q1 2025, and up 138.75% quarter-over-quarter from -$240000.0 in Q4 2025.
Purple Biotech (PPBT) Share-based Compensation (IS) (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Share-based Compensation (IS) data on file, last reported at $93000.0 in Q1 2026.
- Share-based Compensation (IS) for Q1 2026 came in at $93000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $112000.0 (up 13.13% YoY), and the FY2025 annual result was $309000.0, down 46.91% from the prior year.
- Share-based Compensation (IS) advanced to $93000.0 in Q1 2026 per PPBT's latest filing, from -$240000.0 in the prior quarter.
- Over five years, Share-based Compensation (IS) peaked at $839000.0 in Q4 2022 and troughed at -$344000.0 in Q4 2024.
- A 5-year average of $280235.3 and a median of $218000.0 in 2024 frame the typical range for Share-based Compensation (IS).
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation (IS) soared 175.08% in 2022, then tumbled 290.06% in 2024.
- A 5-year view of Share-based Compensation (IS) shows it stood at $839000.0 in 2022, then sank by 78.43% to $181000.0 in 2023, then plunged by 290.06% to -$344000.0 in 2024, then jumped by 30.23% to -$240000.0 in 2025, then jumped by 138.75% to $93000.0 in 2026.
- Business Quant data shows PPBT's Share-based Compensation (IS) at $93000.0 in Q1 2026, -$240000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.45 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 892,057.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 14.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Purple Biotech | 261.30 Mn | 254.88 Mn | - | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | -240,000.00 |
| Dec 31, 2025 | -240,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -344,000.00 |
| Dec 31, 2024 | -344,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |